Document is current
Any future updates will be listed below
-
Authors
Peerlings, Jurgen
Woodruff, Henry C. https://orcid.org/0000-0001-7911-5123
Winfield, Jessica M.
Ibrahim, Abdalla
Van Beers, Bernard E.
Heerschap, Arend
Jackson, Alan https://orcid.org/0000-0002-1623-0383
Wildberger, Joachim E.
Mottaghy, Felix M.
DeSouza, Nandita M.
Lambin, Philippe
- License Information
-
More Information
Article History
Received: 30 May 2018
Accepted: 5 March 2019
First Online: 18 March 2019
Competing Interests
: Dr. Philippe Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic, Health Innovation Ventures and DualTpharma. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics, BHV, Merck and Convert pharmaceuticals. Dr. Lambin has shares in the company Oncoradiomics SA and Convert pharmaceuticals SA and is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures. Dr. Woodruff has (minority) shares in the company Oncoradiomics. Dr. Wildberger reports institutional grants from Agfa, Bard, Bayer, GE, Optimed, Philips, Siemens and personal fees (Speaker’s Bureau) from Bayer and Siemens outside the submitted work.
